Amylin Pharmaceuticals and Eli Lilly and Company jointly developed and launched Byetta®, approved by the FDA in April 2005 as adjunctive therapy to improve blood-sugar control in patients with type 2 diabetes who have not achieved adequate control on metformin and/or a sulfonylurea, two common oral diabetes medications. Amylin and Lilly are working together to develop a once-weekly, long-acting formulation of exenatide, a subcutaneous injection of exenatide for the treatment of type 2 diabetes. Once-weekly exenatide has not been approved by the FDA for marketing in the United States or by regulatory agencies elsewhere in the world.
For more information about Amylin Pharmaceuticals, visit www.amylin.com.
"We have a common enemy in diabetes and we share a common thread with Lilly to do what's right for patients. Our collaboration with Lilly is built on trust and a desire to utilize the skills and strengths of both companies to fight this disease. Together we have developed and commercialized Byetta, a first-in-class diabetes drug that provides durable glucose control with weight loss and illustrates our commitment to bringing life-changing therapeutics to patients. At Amylin we focus on Challenging Science and Changing Lives. Lilly focuses on providing answers that matter through medicine and information. Together, through our alliance, we are working to bring additional innovative medicines to caregivers and patients to fight the disease of diabetes."
Orville G. Kolterman, M.D.
Senior Vice President, Research and Development, Amylin Pharmaceuticals, Inc.
"Lilly's alliance with Amylin, formed in 2002, is a collaboration with a shared vision and common goals. We are dedicated to improving the lives and overall health of our patients through innovative, patient-focused therapy. Amylin is an innovator in the development and commercialization of next-generation diabetes therapies. Working together, we have brought forward Byetta, a significant advance in the treatment of type 2 diabetes, and are continuing to innovate via once-weekly and other formulations. Our alliance has capitalized on the strengths of both organizations and is dependent upon the ongoing commitment of our teams. Throughout our collaboration, Amylin and Lilly have leveraged our individual strengths to develop and commercialize the exenatide program. We look forward to continuing success with Amylin."
Dave Vondle
Byetta Global Product Development Leader, Research and Development, Eli Lilly and Company
